According to a new market report published by Transparency Market Research “U.S. Vaccine Market - Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020,” the U.S. vaccine market was valued at USD 12.8 billion in 2013 and is expected to grow at a CAGR of 4.3% from 2014 to 2020, to reach an estimated value of USD 17.3 billion in 2020.
Browse the full U.S. Vaccine Market (Human Vaccines: Hepatitis, Influenza, Meningococcal, Pneumococcal, HPV, Combination Vaccines; Animal Vaccines: Canine, Feline, Porcine, Bovine, Ovine, Poultry and Equine) - Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020 report at https://www.transparencymarketresearch.com/us-vaccine-market.html
Earlier, the only way to achieve immunity against a disease was through infection with the actual disease, which is known as naturally-acquired immunity. Today, a number of vaccines are available that are administered to boost immunity against various diseases. The U.S. Centers for Disease Control and Prevention (CDC)’s Advisory Committee on Immunization Practices (ACIP) recommends vaccination against many diseases including hepatitis A, hepatitis B, influenza, meningococcal, pneumococcal, human papillomavirus (HPV), polio, rabies, rotavirus, varicella and Japanese encephalitis, among others. The U.S. vaccine market is growing under the influence of factors such as rising awareness regarding vaccination through various governmental and non-profit organizations, extremely low risk of serious and fatal side effects associated with vaccines and burgeoning demand for adult vaccines. On the contrary, stringent regulatory approval process, high cost associated with new vaccine discovery and development, and burden of maintaining cold chain logistics to prevent loss of vaccine potency and efficacy are some major factors creating hindrance in the growth of vaccine market.
The U.S. vaccine market is majorly segmented into human and animal vaccines. The market for U.S. human vaccines has been further classified into pediatric and adult vaccine markets. The pediatric vaccine market represented the larger segment by revenue in 2013. However, during the forecast period from 2014 to 2020, the market for adult vaccines is expected to expand at a higher CAGR than the pediatric vaccines market. One of the major reasons for this is the CDC’s recommendations to adults for immunization against several diseases such as flu, pneumococcal, meningococcal, HPV infection, chickenpox and hepatitis. The CDC’s recommendations to all U.S. citizens aged 6 months and older travelling abroad to be up-to-date on routine vaccines and travel vaccines, also contribute to the market growth of adult vaccines.
On the basis of different antigens, the U.S. human vaccine market is segmented into hepatitis, influenza, meningococcal, pneumococcal, HPV, combination vaccines, and others. Of these, the combination vaccines segment held the largest share by revenue in 2013, though meningococcal vaccines are likely to form the fastest growing segment during the forecast period. This is primarily due to the anticipated launch of pipeline products in this segment during the forecast period. The U.S. human vaccine market is dominated by five major vaccine manufacturers: GlaxoSmithKline plc, Sanofi, Pfizer Ltd, Merck & Co., Inc., and Novartis International AG. These players collectively accounted for more than 85% of the total market revenue in 2013.
The U.S. animal vaccine market has been broadly classified as companion and livestock vaccine markets. The companion animal vaccine market segment has been further categorized into canine and feline, while the livestock vaccines market segment has been divided into porcine, bovine, ovine, poultry and equine sub-segments. Within the livestock vaccine market, bovine vaccine market represented the largest segment in terms of revenue in 2013. However, during the forecast period between 2014 and 2020, the poultry vaccine market is expected grow at the highest rate. Zoetis, Inc., Merck & Co., Inc. (Merck Animal Health), Sanofi (Merial, animal health division of Sanofi) and Boehringer Ingelheim are the leading players in the U.S. animal vaccine market.
The U.S. vaccine market is segmented as follows:
U.S. Human Vaccine Market, by Type
U.S. Human Vaccine Market, by Antigen
- Hepatitis (A & B)
- Human Papillomavirus (HPV)
- Combination Vaccines (DTaP, DTaP-Hep B-IPV, DTaP-IPV and DTaP-IPV)
U.S. Animal Vaccine Market, by Animal Type
- Companion Animal Vaccine Market
- Livestock Vaccine Market
Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
90 State Street, Suite 700
Albany, NY 12207
USA - Canada Toll Free: 866-552-3453